Invention Grant
- Patent Title: Cyclin G1 inhibitors and related methods of treating cancer
-
Application No.: US16483308Application Date: 2018-02-02
-
Publication No.: US11325958B2Publication Date: 2022-05-10
- Inventor: Erlinda M. Gordon , Frederick L. Hall
- Applicant: DELTA NEXT-GENE, LLC
- Applicant Address: US CA Santa Monica
- Assignee: DELTA NEXT-GENE, LLC
- Current Assignee: DELTA NEXT-GENE, LLC
- Current Assignee Address: US CA Santa Monica
- Agency: Armstrong Teasdale LLP
- International Application: PCT/US2018/016643 WO 20180202
- International Announcement: WO2018/144863 WO 20180809
- Main IPC: C07K14/47
- IPC: C07K14/47 ; A61K38/17 ; A61K47/69 ; C07K7/06 ; C12N9/12 ; G01N33/574 ; G01N33/68 ; A61K38/00

Abstract:
Methods of treating a cancer in a patient are provided. The methods can include obtaining a tumor sample from a patient, detecting whether CCNG1 gene expression is present in the tumor sample, diagnosing the patient with a CCNG1 inhibitor-responsive cancer when the presence of CCNG1 gene expression in the tumor sample is detected, and/or administering an effective amount of a CCNG1 inhibitor to the diagnosed patient. CCNG1 inhibitors can include a viral vector having a binding peptide that is configured to bind one or more signature (SIG) elements of an invading tumor and at least one cytocidal gene. CCNG1 inhibitors including cell penetrating peptides are also provided.
Public/Granted literature
- US20190382459A1 CYCLIN G1 INHIBITORS AND RELATED METHODS OF TREATING CANCER Public/Granted day:2019-12-19
Information query